-
Signature
-
/s/ Vanina de Verneuil, Attorney-In-Fact
-
Issuer symbol
-
VIR
-
Transactions as of
-
24 Feb 2026
-
Net transactions value
-
-$140,720
-
Form type
-
4
-
Filing time
-
26 Feb 2026, 16:54:33 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| De Backer Marianne |
Chief Executive Officer, Director |
C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO |
/s/ Vanina de Verneuil, Attorney-In-Fact |
26 Feb 2026 |
0001797819 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
VIR |
Common Stock |
Sale |
$140,720 |
-14,762 |
-1.4% |
$9.53 |
1,020,704 |
24 Feb 2026 |
Direct |
F1 |
| holding |
VIR |
Common Stock |
|
|
|
|
|
53,118 |
24 Feb 2026 |
See Footnote |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: